Annexin Pharmaceuticals
0,461
SEK
-4,55 %
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 investorer følger denne virksomhed
-4,55%
-10,66%
-13,02%
+18,51%
+88,41%
+71,88%
-28,32%
-40,05%
-85,92%
annexinpharma.com/investors
Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
ANNX
Daglig lav / høj pris
0,45 / 0,495
SEK
Markedsværdi
245,7 mio. SEK
Aktieomsætning
201,96 t SEK
Volumen
428 t
Finanskalender
Årsrapport
06.02.2025
Delårsrapport
16.04.2025
Generalforsamling
15.05.2025
Delårsrapport
17.07.2025
Delårsrapport
23.10.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Mikael Lönn | 26,0 % | 26,0 % |
| Arne Andersson | 10,9 % | 10,9 % |
| Jahreskog, Sebastian | 9,3 % | 9,3 % |
| Avanza Pension | 9,2 % | 9,2 % |
| Claesson, Magnus | 8,2 % | 8,2 % |
| Lars Hallén | 3,8 % | 3,8 % |
| Nordnet Pensionsförsäkring AB | 3,0 % | 3,0 % |
| Willman, Mattias | 2,9 % | 2,9 % |
| Fridh, Thorbjörn | 2,4 % | 2,4 % |
| Medirista AB | 1,6 % | 1,6 % |
ViserAlle indholdstyper
Redeye: Annexin Q3 - Presented positive top-line data during the quarter
Annexin Pharmaceuticals AB: BioStock: Annexin: Could ANXV replace anti-VEGFs?
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools